Siren Biotechnology
About this raise
Siren Biotechnology, with a valuation of $60 million, is raising funds on Wefunder. The company is focused on fighting cancer with AAV immuno-gene therapy. Siren Biotechnology is merging the precision of gene therapy with the power of immunotherapy to create a universal adeno-associated virus immune-gene therapy that will make cancer treatment scalable, accessible, and effective. The business won the 2025 Startup of The Year award at Phacilitate Advanced Therapies Week and has received $4 million in competitive grant awards from the California Institute for Regenerative Medicine. Dr. Nicole K. Paulk founded Siren Biotechnology in September 2020. The current crowdfunding campaign has a minimum target of $49,995.66 and a maximum target of $4.99 million. The campaign proceeds will be used for non-clinical trials, drug product manufacturing, regulatory preparations, and clinical trial preparation for SRN-101, technological innovations, and operational expenses.
Investment Overview
Committed $59,928 :
Deal Terms
Company & Team
Company
- Year Founded
- 2020
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Location
- San Francisco, California
- Company Website
-
Visit Website
Team
- Employees
- 6
Financials
-
Revenue
-
$0
as of FY2024
- Monthly Burn
-
$388,889
as of FY2024
-
Runway
-
24+ months
as of FY2024
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Company Funding & Growth
Funding history
Close Date | Platform | Valuation | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|
07/09/2025 | Wefunder | $60,000,000 | $59,928 | Equity - Preferred | Active | RegCF |